

FOR IMMEDIATE RELEASE

COTI-2 FOUND TO CORRECT SPECIFIC p53 GENE MUTATION IN HUMAN OVARIAN CANCER CELLS

Mutation common in many human cancers

London, Ontario (December 13, 2012): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) released important new test results today proving that COTI-2, the company's lead oncology candidate, stops cancer cells from replicating by correcting the effects of specific genetic errors affecting the p53 gene. COTI's previous research had identified a strong statistical relationship between the presence of several p53 mutations and COTI-2's in-vitro effectiveness in cancer cell lines with these mutations.

"Our experiments showed that COTI-2, at a low dose, restored the normal protein configuration of the R175H p53 gene mutation and did not affect normal p53 protein," said Dr. Wayne Danter, COTI's President and CEO. "The R175H variant is found in many human cancers with additional strong statistical evidence suggesting that COTI-2 is highly effective in at least two other p53 'HotSpot' mutations found in about 20% of all human cancers. Additional experiments are planned to confirm the effect of COTI-2 on these other common p53 mutations (R248W and R273H)."

This new information represents an important advance in the understanding of COTI-2's specific gene mutation mechanism of action with the results extending the test outcomes generated by Dr. Yu et al from the University of New Jersey as published in the May 2012 edition of the journal, Cancer Cell.

In the experiments:

1. A human ovarian cancer cell line (TOV-112D) that expresses the specific p53 mutation, R175H, was treated with a low concentration of COTI-2. Analysis of fluorescent antibody and protein quantification data from the treated cells confirmed that COTI-2 restored p53 protein to normal configuration in these human ovarian cancer cells. This restoration of normal function then leads to cancer cell death.
2. A human lung cancer cell line (H460) expressing normal p53 protein was also treated with a low concentration of COTI-2 as a control. The analysis of fluorescent antibody and protein quantification data from this cell line confirmed that treatment with COTI-2 did not affect the normal p53 protein in these human lung cancer control cells.

3. The gene mutation specific normalization of p53 protein configuration was observed at a very low concentration (10 nmol/l) that is easily achievable when COTI-2 is given orally.

“With this and other exciting new mechanism of action data we have decided to engage Destum Partners, a boutique advisory firm, in order to help bring new potential partners into dialogue and meet our timelines in securing a partnership for COTI-2. As such, all business development related inquiries should be directed to Destum Partners Inc.” concluded Dr. Danter.

About Critical Outcome Technologies Inc.

COTI is a leading-edge company specializing in accelerating the discovery of small molecules thus enabling these new drugs to be brought to market in a more cost effective, efficient and timely manner. COTI'S proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with high probability of being successfully incorporated in disease-specific drug discovery, as well as subsequent optimization and preclinical development. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Dr. Wayne Danter, President and CEO

wdanter@criticaloutcome.com

About Destum Partners, Inc.

Destum is a boutique consulting and advisory firm designed to effectively meet the demands of the Biopharmaceutical and Life Sciences industries. Destum serves an exclusive clientele dedicated to pushing the boundaries of technology innovation to improve the quality of life of humanity. Our Clients range from multinational pharmaceutical corporations to private early stage biotechnology companies throughout the globe. Destum's advisory services include buy and sell side advisory, M&A, licensing, and research collaborations. Destum's consulting services include Product and Market Assessments and Asset Valuations which are powered by a cross functional team that brings scientific, market, commercial, and financial expertise together to provide insightful and actionable guidance.

For more information, please visit www.destumpartners.com or contact:

Michael Cozart, Senior Associate

mcozart@destumpartners.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.